SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-031982
Filing Date
2023-09-07
Accepted
2023-09-07 16:30:42
Documents
22
Period of Report
2023-08-31
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 42914
2 ex3-1.htm EX-3.1 2579
3 ex3-2.htm EX-3.2 3366
4 ex3-1_001.jpg GRAPHIC 245526
5 ex3-1_002.jpg GRAPHIC 276537
6 ex3-1_003.jpg GRAPHIC 158310
7 ex3-2_001.jpg GRAPHIC 166170
8 ex3-2_002.jpg GRAPHIC 245622
9 ex3-2_003.jpg GRAPHIC 276537
10 ex3-2_004.jpg GRAPHIC 136571
  Complete submission text file 0001493152-23-031982.txt   2342585

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE bct-20230831.xsd EX-101.SCH 3744
12 XBRL DEFINITION FILE bct-20230831_def.xml EX-101.DEF 26582
13 XBRL LABEL FILE bct-20230831_lab.xml EX-101.LAB 36619
14 XBRL PRESENTATION FILE bct-20230831_pre.xml EX-101.PRE 25206
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5329
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 231242649
SIC: 2834 Pharmaceutical Preparations